Skip to main content
Premium Trial:

Request an Annual Quote

RenalytixAI, Wake Forest, Atrium Health Partner on Kidney Health Initiative

NEW YORK – RenalytixAI said on Wednesday that it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement a clinical care model to improve kidney health and reduce kidney disease progression and failure in high-risk populations.

As part of the collaboration, New York-based RenalytixAI will offer its KidneyIntelX platform through Atrium Health's electronic health record, or EHR, system. Primary care physicians, endocrinologists, nephrologists, and care teams at 37 hospitals and more than 1,350 care locations in the Carolinas and Georgia will have access to the platform.

KidneyIntelX uses an artificial intelligence-based algorithm to integrate diverse data inputs, such as blood-based biomarkers, inherited genetics, and personalized patient data from EHRs to produce a risk score to predict progressive kidney function decline in CKD.

RenalytixAI said it plans to co-locate personnel in Winston-Salem, North Carolina, to support the collaboration with Wake Forest School of Medicine at the Innovation Quarter's iQ HealthTech Labs.

The program will initially target diabetes-associated kidney disease in the region, which has been designated by the Centers for Disease Control and Prevention as the "diabetes belt" and "kidney disease belt."

"Initiatives focused on the generation of unique data-driven insights to improve patient outcomes enable us to deliver effective education and care pathways to improve care and outcomes," Terry Williams, chief population, corporate, and government affairs officer of Atrium Health, said in a statement. "Together, we are innovating to achieve clinical excellence and are laying the foundation for patient and physician access to advanced prognostic precision medicine in a major chronic disease."

RenalytixAI believes the partnership will allow focused population health initiatives in kidney disease and will provide real-world evidence of delivery of care, improved quality of life, and reduced healthcare costs.

"This effort is critical to optimizing care and improving outcomes using kidney protective medications, specialist referrals, and lifestyle changes," said Barry Freedman, chief of nephrology at Wake Forest School of Medicine, in a statement. "KidneyIntelX can help us better allocate clinical resources across Atrium Health’s southeastern service region."

RenalytixAI also noted that the partnership will involve a five-year, multicenter evidence development program across the region, where patients with chronic kidney disease will receive the KidneyIntelX test as part of a care solution to drive improvements in patient outcomes. The assay will also be broadly available to patients with both private and government insurance.

RenalytixAI will also provide financial support to Atrium Health in the form of collaborative research and development, digital health technology deployment, education program delivery, and third-party resources.

In April, RenalytixAI landed a US governmental contract that enables testing services using the KidneyIntelX assay.